It's what's inside that counts
Acura's midsize sedan, the TL, received some styling updates this past year, making it even more appealing than it was.
But probably more significant for consumers is the addition of a six-speed automatic transmission, which helped boost the car's highway fuel economy.
EPA ratings are now 20 mpg city/29 highway for the TL with the base 3.5-liter V-6 engine, up from 2 0/25 in the previous model, which came with a five-speed automatic.
No changes are planned for the 2013 version, which goes on sale this fall.
For the 2012 model, prices range from $35,705-$45,185.
The $35,705 price brings the entry-level, front-wheel-drive TL with the base V-6 engine. For $45,185, you'll get everything that's available in a TL, including all-wheel drive, a more-powerful 3.7-liter V-6, and both the Advance and Technology packages.
We tested the top-of-the-line model, which even had such extras as a power trunk lid, blind-spot monitoring, and one of the best audio systems around.
The 3.5-liter engine, rated at 280 horsepower, was given some friction-reduction technologies to help boost fuel efficiency, Acura said.
The six-speed automatic has Acura's Sequential SportShift feature, which allows for manual shifting without having to use a clutch.
Design tweaks included a new front bumper with improved aerodynamics, a new grille, revised headlights and a shorter front overhang.
There are smaller rear reflectors, new LED taillights and a thinner trunk-edge trim.
The changes were a “freshening,” rather than a complete makeover.
Show commenting policy
TribLive commenting policy
You are solely responsible for your comments and by using TribLive.com you agree to our Terms of Service.
We moderate comments. Our goal is to provide substantive commentary for a general readership. By screening submissions, we provide a space where readers can share intelligent and informed commentary that enhances the quality of our news and information.
While most comments will be posted if they are on-topic and not abusive, moderating decisions are subjective. We will make them as carefully and consistently as we can. Because of the volume of reader comments, we cannot review individual moderation decisions with readers.
We value thoughtful comments representing a range of views that make their point quickly and politely. We make an effort to protect discussions from repeated comments either by the same reader or different readers.
We follow the same standards for taste as the daily newspaper. A few things we won't tolerate: personal attacks, obscenity, vulgarity, profanity (including expletives and letters followed by dashes), commercial promotion, impersonations, incoherence, proselytizing and SHOUTING. Don't include URLs to Web sites.
We do not edit comments. They are either approved or deleted. We reserve the right to edit a comment that is quoted or excerpted in an article. In this case, we may fix spelling and punctuation.
We welcome strong opinions and criticism of our work, but we don't want comments to become bogged down with discussions of our policies and we will moderate accordingly.
We appreciate it when readers and people quoted in articles or blog posts point out errors of fact or emphasis and will investigate all assertions. But these suggestions should be sent via e-mail. To avoid distracting other readers, we won't publish comments that suggest a correction. Instead, corrections will be made in a blog post or in an article.
- Former athletes open businesses
- Apprenticeship programs fill gaps in American manufacturing
- Chevron laying off 162 workers from Moon-based unit
- Password change can block hackers from wireless cameras
- Workarounds exist for battery woes
- Interest in hybrid, electric vehicles declines while gas prices fall
- Typewriters back in style, keeping repair shops busy
- First-time home-buyers expected to pump up sales in 2015
- Energy industry says it’s on top of methane leaks, but environmentalists want oversight
- U.S. Steel plans to close two plants affecting 545 workers
- Mylan loses Supreme Court fight over multiple sclerosis drug